The Asia Pacific Lysosomal Disease Treatment Market would witness market growth of 7.3% CAGR during the forecast period (2022-2028).
The inactivated, late-onset form of Gaucher disease (type 1 disease) is characterized by hepatosplenomegaly and skeletal involvement. However, the macrophages of the reticuloendothelial system must break down vast quantities of glycosphingolipid because of their function in the phagocytosis of effete blood cells. Specific people fall between these two phenotypes and have skeletal and systemic disease as well as brainstem involvement (traditionally known as type 3 disease), which raises the possibility that some neuronal subtypes are especially sensitive to glucocerebrosidase deficiency.
The genotype-phenotype correlation at least partially supports this theory, because some "severe" genotypes are invariably linked to neuronopathic illness in homozygotes or complex heterozygotes. However, the majority of mutations that result in attenuated disease have much less clearly defined genotype/phenotype relationships, and sibling pairs and even twins frequently exhibit clinical features that are very different from one another in terms of age of onset and degree of skeletal involvement. The problems in predicting phenotypic from genotype have significant consequences in disorders for which newborn screening is currently being studied.
A National Policy for the Treatment of Rare Diseases (NPTRD) was created by the Ministry of Health and Family Welfare of the Government of India in July 2017. The policy's implementation, however, ran into several issues. Hospitals and public health are primarily state concerns. At the draught stage of policy formulation, extensive stakeholder participation with the State Governments was not possible.
During the sharing of the policy with State Governments, some expressed concerns, including the cost-effectiveness of initiatives for rare diseases compared to other health priorities, the allocation of expenditures between the Central and State Governments, and the flexibility of the State Governments to accept or modify the policy. The growing awareness of lysosomal drives the growth of the lysosomal disease treatment market.
The China market dominated the Asia Pacific Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $831.6 Million by 2028. The Japan market is experiencing a CAGR of 6.7% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 8% during (2022 - 2028).
Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Lysosomal Disease Treatment Market is Projected to reach USD 11 Billion by 2028, at a CAGR of 6.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Gaucher's Diseases
- Fabry Diseases
- Mucopolysaccharidosis
- Pompe’s Syndrome
- Others
By Type of Therapy
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Stem Cell Therapy
- Others
By End User
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Eli Lilly And Company
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- BioMarin Pharmaceutical Inc.
- Sigilon Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Lysosomal Disease Treatment Market, by Disease Type
1.4.2 Asia Pacific Lysosomal Disease Treatment Market, by Type of Therapy
1.4.3 Asia Pacific Lysosomal Disease Treatment Market, by End User
1.4.4 Asia Pacific Lysosomal Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Lysosomal Disease Treatment Market by Disease Type
3.1 Asia Pacific Gaucher's Diseases Market by Country
3.2 Asia Pacific Fabry Diseases Market by Country
3.3 Asia Pacific Mucopolysaccharidosis Market by Country
3.4 Asia Pacific Pompe’s Syndrome Market by Country
3.5 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy
4.1 Asia Pacific Enzyme Replacement Therapy Market by Country
4.2 Asia Pacific Substrate Reduction Therapy Market by Country
4.3 Asia Pacific Stem Cell Therapy Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Lysosomal Disease Treatment Market by End User
5.1 Asia Pacific Hospitals Market by Country
5.2 Asia Pacific Clinics Market by Country
5.3 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Lysosomal Disease Treatment Market by Country
6.1 China Lysosomal Disease Treatment Market
6.1.1 China Lysosomal Disease Treatment Market by Disease Type
6.1.2 China Lysosomal Disease Treatment Market by Type of Therapy
6.1.3 China Lysosomal Disease Treatment Market by End User
6.2 Japan Lysosomal Disease Treatment Market
6.2.1 Japan Lysosomal Disease Treatment Market by Disease Type
6.2.2 Japan Lysosomal Disease Treatment Market by Type of Therapy
6.2.3 Japan Lysosomal Disease Treatment Market by End User
6.3 India Lysosomal Disease Treatment Market
6.3.1 India Lysosomal Disease Treatment Market by Disease Type
6.3.2 India Lysosomal Disease Treatment Market by Type of Therapy
6.3.3 India Lysosomal Disease Treatment Market by End User
6.4 South Korea Lysosomal Disease Treatment Market
6.4.1 South Korea Lysosomal Disease Treatment Market by Disease Type
6.4.2 South Korea Lysosomal Disease Treatment Market by Type of Therapy
6.4.3 South Korea Lysosomal Disease Treatment Market by End User
6.5 Singapore Lysosomal Disease Treatment Market
6.5.1 Singapore Lysosomal Disease Treatment Market by Disease Type
6.5.2 Singapore Lysosomal Disease Treatment Market by Type of Therapy
6.5.3 Singapore Lysosomal Disease Treatment Market by End User
6.6 Malaysia Lysosomal Disease Treatment Market
6.6.1 Malaysia Lysosomal Disease Treatment Market by Disease Type
6.6.2 Malaysia Lysosomal Disease Treatment Market by Type of Therapy
6.6.3 Malaysia Lysosomal Disease Treatment Market by End User
6.7 Rest of Asia Pacific Lysosomal Disease Treatment Market
6.7.1 Rest of Asia Pacific Lysosomal Disease Treatment Market by Disease Type
6.7.2 Rest of Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy
6.7.3 Rest of Asia Pacific Lysosomal Disease Treatment Market by End User
Chapter 7. Company Profiles
7.1 Merck & Co., Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Johnson & Johnson (Janssen Global Services, LLC)
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Eli Lilly And Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Acquisition and Mergers:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 Takeda Pharmaceutical Company Limited
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.6 Sanofi S.A.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 BioMarin Pharmaceutical Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Approvals and Trials:
7.10. Sigilon Therapeutics, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
TABLE 1 Asia Pacific Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Gaucher's Diseases Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Gaucher's Diseases Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Fabry Diseases Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Fabry Diseases Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Mucopolysaccharidosis Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Mucopolysaccharidosis Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Pompe’s Syndrome Market by Country, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Pompe’s Syndrome Market by Country, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Enzyme Replacement Therapy Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Enzyme Replacement Therapy Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Substrate Reduction Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Substrate Reduction Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 Asia Pacific Stem Cell Therapy Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific Stem Cell Therapy Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 25 Asia Pacific Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 26 Asia Pacific Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 27 Asia Pacific Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 28 Asia Pacific Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 29 Asia Pacific Clinics Market by Country, 2018 - 2021, USD Million
TABLE 30 Asia Pacific Clinics Market by Country, 2022 - 2028, USD Million
TABLE 31 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 32 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 33 Asia Pacific Lysosomal Disease Treatment Market by Country, 2018 - 2021, USD Million
TABLE 34 Asia Pacific Lysosomal Disease Treatment Market by Country, 2022 - 2028, USD Million
TABLE 35 China Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 36 China Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 37 China Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 China Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 China Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 40 China Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 41 China Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 42 China Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 43 Japan Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 44 Japan Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 45 Japan Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 Japan Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 Japan Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 48 Japan Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 49 Japan Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 50 Japan Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 51 India Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 52 India Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 53 India Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 India Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 India Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 56 India Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 57 India Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 58 India Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 59 South Korea Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 60 South Korea Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 61 South Korea Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 South Korea Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 South Korea Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 64 South Korea Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 65 South Korea Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 66 South Korea Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 67 Singapore Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 68 Singapore Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 69 Singapore Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 Singapore Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 Singapore Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 72 Singapore Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 73 Singapore Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 74 Singapore Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 75 Malaysia Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 76 Malaysia Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 77 Malaysia Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Malaysia Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Malaysia Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 80 Malaysia Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 81 Malaysia Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 82 Malaysia Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 83 Rest of Asia Pacific Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 84 Rest of Asia Pacific Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 85 Rest of Asia Pacific Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 86 Rest of Asia Pacific Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 87 Rest of Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 88 Rest of Asia Pacific Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 89 Rest of Asia Pacific Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 90 Rest of Asia Pacific Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 91 KEY INFORMATION - MERCK & CO., INC.
TABLE 92 Key information –Johnson & Johnson
TABLE 93 Key Information – Eli Lilly And Company
TABLE 94 Key Information – Pfizer, Inc.
TABLE 95 Key Information – Takeda Pharmaceutical Company Limited
TABLE 96 Key Information – Sanofi S.A.
TABLE 97 Key Information – Novartis AG
TABLE 98 KEY INFORMATION – ASTRAZENECA PLC
TABLE 99 Key Information – BioMarin Pharmaceutical Inc.
TABLE 100 Key Information – Sigilon Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research